GlassScriptPhysician profile
Jamie K Mccartney Herbert
NPI 1679062855
$2,744.23
in general payments reported to CMS, 2019-2025
19 companies · $37.27 in 2025
The $37.27 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,947 · 2023: $740 · 2024: $19.98 · 2025: $37.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $503.60 | 2022-2023 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $416.17 | 2022-2023 | Ingrezza |
| Abbvie INC. | $385.95 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $344.71 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $188.49 | 2022-2023 | Nuedexta, Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $143.46 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $141.34 | 2022-2023 | Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $134.81 | 2022 | |
| Corium, LLC | $133.29 | 2022-2023 | Azstarys |
| Lundbeck LLC | $106.09 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $66.17 | 2022-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $34.70 | 2022-2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $33.63 | 2022 | |
| Ironshore Pharmaceuticals INC. | $32.79 | 2022-2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $17.28 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.11 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $15.08 | 2023 | Contrave |
| Alfasigma USA, INC. | $15.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.54 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Mccartney Herbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.